Document is current
Any future updates will be listed below
-
Authors
Giles, Josephine R.
Ngiow, Shin Foong
Manne, Sasikanth
Baxter, Amy E. https://orcid.org/0000-0002-1555-0713
Khan, Omar
Wang, Ping
Staupe, Ryan
Abdel-Hakeem, Mohamed S. https://orcid.org/0000-0003-0226-3464
Huang, Hua
Mathew, Divij
Painter, Mark M. https://orcid.org/0000-0002-0180-2748
Wu, Jennifer E.
Huang, Yinghui Jane https://orcid.org/0000-0003-0974-9539
Goel, Rishi R.
Yan, Patrick K.
Karakousis, Giorgos C.
Xu, Xiaowei
Mitchell, Tara C. https://orcid.org/0000-0002-8186-7284
Huang, Alexander C. https://orcid.org/0000-0002-0099-0492
Wherry, E. John https://orcid.org/0000-0003-0477-1956
- License Information
-
More Information
Article History
Received: 20 March 2022
Accepted: 13 September 2022
First Online: 21 October 2022
Competing interests
: E.J.W. is a member of the Parker Institute for Cancer Immunotherapy, which supported the study. E.J.W. is an advisor for Danger Bio, Marengo, Janssen, Pluto Immunotherapeutics, Related Sciences, Rubius Therapeutics, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio and Arsenal Biosciences. E.J.W. has a patent on the PD-1 pathway. O.K. holds equity in Arsenal Biosciences and is an employee of Orange Grove Bio. A.C.H. is a consultant for Immunai and receives funding from BMS. X.X. is scientific cofounder of CureBiotech and Exio Biosciences. T.M. is on the scientific advisory board for Merck, BMS, OncoSec, GigaGen and Instil Bio. G.C.K. is on the scientific advisory board for Merck and was the principal investigator of an investigator-initiated trial sponsored by Merck.
